Article number: K 7809
Standard concentrations included in the kit
Possible sample matrix and volumes
|EDTA plasma||50 µl|
Autoantibodies against oxidized LDL (low density liporotein) represent an endogenous protection against oxidised LDL and prevent its penetration through the vessel wall and thus pathological accumulation in arteries.
Oxidized LDL is changed by oxidation to such an extent that it becomes immunogenic and can trigger an immunological reaction. These specific autoantibodies against oxidation-specific epitopes (OSE) of oxidized LDL can be detected in serum. In this process, B1 cells produce so-called natural IgM-type antibodies against oxidized LDL in response to T-cell-independent antigens. These reduced the extent of atherosclerotic lesions and hindered the uptake of oxLDL by macrophages in animal models. In humans, an inverse correlation was shown between circulating OSE-specific IgM antibodies and cardiovascular events. B2 cells produce IgG antibodies against oxLDL, which show a positive correlation with the presence of cardiovascular disease.
These ox-LDL antibodies recognize tissue from atherosclerotic lesions. The titre of antibodies against oxidized LDL is considered an independent indicator of the progression of atherosclerosis.